BriaCell Therapeutics Corp.
BCT.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.71M | 6.56M | 6.55M | 6.39M | 6.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.03M | 30.74M | 30.37M | 27.20M | 24.42M |
| Operating Income | -32.03M | -30.74M | -30.37M | -27.20M | -24.42M |
| Income Before Tax | -30.98M | -29.96M | -29.01M | -26.56M | -19.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.98 | -29.96 | -29.01 | -26.56 | -19.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 301.10K | 326.60K | 297.90K | 244.20K | 206.10K |
| Net Income | -30.68M | -29.64M | -28.71M | -26.31M | -19.43M |
| EBIT | -32.03M | -30.74M | -30.37M | -27.20M | -24.42M |
| EBITDA | -31.92M | -30.63M | -30.27M | -27.10M | -24.27M |
| EPS Basic | -17.14 | -32.58 | -53.31 | -81.62 | -82.59 |
| Normalized Basic EPS | -10.72 | -20.27 | -33.18 | -50.80 | -51.29 |
| EPS Diluted | -17.16 | -32.59 | -53.32 | -81.64 | -82.59 |
| Normalized Diluted EPS | -10.72 | -20.27 | -33.18 | -50.80 | -51.29 |
| Average Basic Shares Outstanding | 12.81M | 5.94M | 3.40M | 1.70M | 939.90K |
| Average Diluted Shares Outstanding | 12.81M | 5.94M | 3.40M | 1.70M | 939.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |